WO2007021672A3 - Vaccination against dengue virus infection - Google Patents
Vaccination against dengue virus infection Download PDFInfo
- Publication number
- WO2007021672A3 WO2007021672A3 PCT/US2006/030846 US2006030846W WO2007021672A3 WO 2007021672 A3 WO2007021672 A3 WO 2007021672A3 US 2006030846 W US2006030846 W US 2006030846W WO 2007021672 A3 WO2007021672 A3 WO 2007021672A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus infection
- dengue virus
- vaccination against
- against dengue
- vaccination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002618783A CA2618783A1 (en) | 2005-08-10 | 2006-08-09 | Vaccination against dengue virus infection |
JP2008526124A JP5227172B2 (en) | 2005-08-10 | 2006-08-09 | Vaccination against dengue virus infection |
CN2006800373918A CN101287490B (en) | 2005-08-10 | 2006-08-09 | Vaccination against dengue virus infection |
EP06800943A EP1924280A4 (en) | 2005-08-10 | 2006-08-09 | Vaccination against dengue virus infection |
AU2006280144A AU2006280144B2 (en) | 2005-08-10 | 2006-08-09 | Vaccination against dengue virus infection |
US12/063,365 US20080193477A1 (en) | 2005-08-10 | 2006-08-09 | Vaccination Against Dengue Virus Infection |
BRPI0614265-6A BRPI0614265A2 (en) | 2005-08-10 | 2006-08-09 | use of a yellow fever virus vaccine and a chimeric flavivirus vaccine and kit containing such vaccines |
IL189329A IL189329A (en) | 2005-08-10 | 2008-02-06 | Vaccination against dengue virus infection, kit and use of same |
NO20081127A NO20081127L (en) | 2005-08-10 | 2008-03-04 | Vaccination against Dengue virus infection |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70703805P | 2005-08-10 | 2005-08-10 | |
US60/707,038 | 2005-08-10 | ||
US71944805P | 2005-09-22 | 2005-09-22 | |
US60/719,448 | 2005-09-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007021672A2 WO2007021672A2 (en) | 2007-02-22 |
WO2007021672A3 true WO2007021672A3 (en) | 2007-11-22 |
Family
ID=37758084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/030846 WO2007021672A2 (en) | 2005-08-10 | 2006-08-09 | Vaccination against dengue virus infection |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080193477A1 (en) |
EP (1) | EP1924280A4 (en) |
JP (1) | JP5227172B2 (en) |
AR (1) | AR055603A1 (en) |
AU (1) | AU2006280144B2 (en) |
BR (1) | BRPI0614265A2 (en) |
CA (1) | CA2618783A1 (en) |
IL (1) | IL189329A (en) |
MY (1) | MY151051A (en) |
NO (1) | NO20081127L (en) |
TW (1) | TW200740458A (en) |
WO (1) | WO2007021672A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2903605A1 (en) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | IMMUNIZATION METHOD AGAINST THE FOUR SEROTYPES OF DENGUE |
FR2906724B1 (en) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE. |
FR2909286B1 (en) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | IMMUNIZATION METHOD AGAINST THE 4 SEROTYPES OF DENGUE |
JP5848243B2 (en) * | 2009-06-01 | 2016-01-27 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | Immunogenic composition against dengue virus |
US8968996B2 (en) * | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
BRPI0904020B8 (en) | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | vaccine composition against the dengue virus, and kit |
CN108912215A (en) | 2012-04-02 | 2018-11-30 | 北卡罗来纳-查佩尔山大学 | Method and composition for dengue virus epitope |
US20150265695A1 (en) | 2012-07-24 | 2015-09-24 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
SG11201500412TA (en) | 2012-07-24 | 2015-02-27 | Sanofi Pasteur | Vaccine compositions |
BR112015012515B1 (en) | 2012-11-30 | 2023-04-11 | Sanofi Pasteur | USE OF ANTIGENS, NUCLEIC ACID CONSTRUCTS OR VIRAL VECTORS CAPABLE OF EXPRESSING A VIRUS-LIKE PARTICLE (VLP) OF DENGUE AND A VACCINE AGAINST MEASLES, A VACCINE AGAINST MUMPS AND A VACCINE AGAINST RUBELLA |
EP2931310A4 (en) * | 2012-12-14 | 2016-05-25 | Takeda Vaccines Inc | Compositions, methods of administration and uses for trivalent dengue virus formulations |
PE20211814A1 (en) * | 2013-03-15 | 2021-09-14 | Takeda Vaccines Inc | COMPOSITIONS AND METHODS OF CHEMERICAL CONSTRUCTION OF DENGUE VIRUS IN VACCINES |
AU2015217149B2 (en) | 2014-02-11 | 2020-09-10 | Massachusetts Institute Of Technology | Novel full spectrum anti-dengue antibody |
GB201704126D0 (en) * | 2017-03-15 | 2017-04-26 | Blom Nihlén Kim Andrea | Vaccine |
US11268071B2 (en) | 2017-03-30 | 2022-03-08 | Merck Sharp And Dohme Corp. | Addition of nucleases directly to cell culture to facilitate digestion and clearance of host cell nucleic acids |
WO2019069130A1 (en) | 2017-10-05 | 2019-04-11 | Sanofi Pasteur | Compositions for booster vaccination against dengu |
MX2021002586A (en) | 2018-09-05 | 2021-06-08 | Takeda Vaccines Inc | Dengue vaccine unit dose and administration thereof. |
WO2021034349A1 (en) | 2019-08-16 | 2021-02-25 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis a |
WO2021174059A1 (en) | 2020-02-27 | 2021-09-02 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
WO2023147342A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
WO2023158989A1 (en) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
WO2023215383A1 (en) | 2022-05-04 | 2023-11-09 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277638B1 (en) * | 1994-02-17 | 2001-08-21 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US20020155581A1 (en) * | 1997-05-23 | 2002-10-24 | Murphy Brian R. | Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens |
US6696281B1 (en) * | 1997-02-28 | 2004-02-24 | Acambis, Inc. | Chimeric flavivirus vaccines |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
US6676936B1 (en) * | 1988-07-14 | 2004-01-13 | The United States Of America As Represented By The Department Of Health And Human Services. | Chimeric and/or growth-restricted flaviviruses |
US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
WO2001039802A1 (en) * | 1999-12-01 | 2001-06-07 | Oravax, Inc. | Chimeric flavivirus vaccines |
US20040259224A1 (en) * | 2002-05-31 | 2004-12-23 | Farshad Guirakhoo | Tetravalent Dengue vaccines |
US6966281B1 (en) * | 2004-05-05 | 2005-11-22 | Hale James R | Internal combustion device and methods of use |
FR2903605A1 (en) * | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | IMMUNIZATION METHOD AGAINST THE FOUR SEROTYPES OF DENGUE |
FR2906724B1 (en) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE. |
FR2909286B1 (en) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | IMMUNIZATION METHOD AGAINST THE 4 SEROTYPES OF DENGUE |
-
2006
- 2006-08-09 US US12/063,365 patent/US20080193477A1/en not_active Abandoned
- 2006-08-09 EP EP06800943A patent/EP1924280A4/en not_active Ceased
- 2006-08-09 BR BRPI0614265-6A patent/BRPI0614265A2/en not_active Application Discontinuation
- 2006-08-09 WO PCT/US2006/030846 patent/WO2007021672A2/en active Application Filing
- 2006-08-09 JP JP2008526124A patent/JP5227172B2/en not_active Expired - Fee Related
- 2006-08-09 CA CA002618783A patent/CA2618783A1/en not_active Abandoned
- 2006-08-09 AU AU2006280144A patent/AU2006280144B2/en not_active Ceased
- 2006-08-10 MY MYPI20063881 patent/MY151051A/en unknown
- 2006-08-10 TW TW095129386A patent/TW200740458A/en unknown
- 2006-08-10 AR ARP060103502A patent/AR055603A1/en unknown
-
2008
- 2008-02-06 IL IL189329A patent/IL189329A/en not_active IP Right Cessation
- 2008-03-04 NO NO20081127A patent/NO20081127L/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277638B1 (en) * | 1994-02-17 | 2001-08-21 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6696281B1 (en) * | 1997-02-28 | 2004-02-24 | Acambis, Inc. | Chimeric flavivirus vaccines |
US20020155581A1 (en) * | 1997-05-23 | 2002-10-24 | Murphy Brian R. | Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens |
Non-Patent Citations (1)
Title |
---|
GUIRAKHOO ET AL.: "Construction, Safety and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine", J. VIROLOGY, vol. 75, 2001, pages 7290 - 7297, XP008125358 * |
Also Published As
Publication number | Publication date |
---|---|
IL189329A0 (en) | 2008-06-05 |
IL189329A (en) | 2015-07-30 |
AU2006280144B2 (en) | 2012-06-14 |
JP2009504654A (en) | 2009-02-05 |
CA2618783A1 (en) | 2007-02-22 |
NO20081127L (en) | 2008-05-07 |
WO2007021672A2 (en) | 2007-02-22 |
AU2006280144A1 (en) | 2007-02-22 |
TW200740458A (en) | 2007-11-01 |
MY151051A (en) | 2014-03-31 |
BRPI0614265A2 (en) | 2011-03-22 |
AR055603A1 (en) | 2007-08-29 |
JP5227172B2 (en) | 2013-07-03 |
EP1924280A4 (en) | 2008-12-10 |
US20080193477A1 (en) | 2008-08-14 |
EP1924280A2 (en) | 2008-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007021672A3 (en) | Vaccination against dengue virus infection | |
IL233634A0 (en) | Methods, compositions, and kits for the treatment of medical conditions | |
AU2006272804A8 (en) | Concentrated protein lyophilates, methods, and uses | |
EP1943348A4 (en) | Compositions, methods, and kits for amplifying nucleic acids | |
EP1963500A4 (en) | Compositions comprising oriented, immobilized macromolecules and methods for their preparation | |
WO2007146965A3 (en) | Compounds for the treatment of periodontal disease | |
IL211132A0 (en) | Anti-il-6 antibodies, compositions, methods and uses | |
IL186071A0 (en) | Antibodies against ccr5 and uses thereof | |
NO20055686L (en) | Composition, method of preparation thereof, and use thereof. | |
EP1868628A4 (en) | Compounds, compositions and methods for the treatment of poxvirus infections | |
ATE556604T1 (en) | STORAGE-Stable, ALCOHOL-FREE AND HAZARD-FREE MALT BEVERAGE AND CORRESPONDING PROCESS | |
WO2008057396A8 (en) | Canine lyme disease vaccine | |
WO2008105826A3 (en) | Compositions compromising lysostaphin variants and methods of using the same | |
WO2007011711A3 (en) | Paramyxoviridae virus preparations | |
ZA200802176B (en) | Vaccination against dengue virus infection | |
WO2008039164A3 (en) | Immunogenic compositions comprising anthrax spore-associated proteins | |
WO2008063791A3 (en) | Composites and methods of preparation and use thereof | |
WO2005110391A3 (en) | Compounds for treating human papillomavirus | |
DE602006009270D1 (en) | Saccharide fluoro-benzene substimes, method of preparation and use thereof | |
WO2005086637A3 (en) | Anthrax antigens and methods of use | |
WO2007081365A3 (en) | Multiple antigenic agents and methods for using the same | |
WO2008142483A3 (en) | Vaccine compositions and methods of use thereof | |
AU2005905768A0 (en) | Therapeutic methods, compositions and kits | |
AU2005901141A0 (en) | Viral diagnostic method and well for use in same | |
IL188186A0 (en) | Gliomedin, fragments thereof and methods of using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680037391.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006280144 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008526124 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 189329 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/001978 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2618783 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006280144 Country of ref document: AU Date of ref document: 20060809 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2006800943 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006800943 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12063365 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0614265 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080211 |